Cargando…

Cognitive Impairment in Secondary Progressive Multiple Sclerosis: Effect of Disease Duration, Age, and Progressive Phenotype

Background: Cognitive deficits are common in multiple sclerosis (MS) and affect patients at all stages of the disease, regardless of phenotype. Aims: This literature review focuses the cognitive deficits observed in secondary progressive MS (SPMS). It is mainly based on studies that compared the fre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Brochet, Bruno, Clavelou, Pierre, Defer, Gilles, De Seze, Jérôme, Louapre, Céline, Magnin, Eloi, Ruet, Aurélie, Thomas-Anterion, Catherine, Vermersch, Patrick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8870031/ https://www.ncbi.nlm.nih.gov/pubmed/35203948 http://dx.doi.org/10.3390/brainsci12020183

Ejemplares similares

Double-Blind Controlled Randomized Trial of Cyclophosphamide versus Methylprednisolone in Secondary Progressive Multiple Sclerosis
por: Brochet, Bruno, et al.
Publicado: (2017)

Cognitive Impairment in Multiple Sclerosis With Regards to Disease Duration and Clinical Phenotypes
por: Brochet, Bruno, et al.
Publicado: (2019)

Expert Narrative Review of the Safety of Cladribine Tablets for the Management of Relapsing Multiple Sclerosis
por: Clavelou, Pierre, et al.
Publicado: (2023)

MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study
por: Tourbah, Ayman, et al.
Publicado: (2016)

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
por: Fissolo, Nicolás, et al.
Publicado: (2021)

Deciphering Depressive Mood in Relapsing-Remitting and Progressive Multiple Sclerosis and Its Consequence on Quality of Life
por: Lamargue Hamel, Delphine, et al.
Publicado: (2015)

The Place of Immune Reconstitution Therapy in the Management of Relapsing Multiple Sclerosis in France: An Expert Consensus
por: De Sèze, Jerome, et al.
Publicado: (2022)

Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study
por: Vermersch, Patrick, et al.
Publicado: (2012)

Disability progression in multiple sclerosis patients using early first‐line treatments
por: Lefort, Mathilde, et al.
Publicado: (2022)

Excess Mortality in Patients with Multiple Sclerosis Starts at 20 Years from Clinical Onset: Data from a Large-Scale French Observational Study
por: Leray, Emmanuelle, et al.
Publicado: (2015)

Pattern separation performance is decreased in patients with early multiple sclerosis
por: Planche, Vincent, et al.
Publicado: (2017)

Effects of socioeconomic status on excess mortality in patients with multiple sclerosis in France: A retrospective observational cohort study
por: Wilson, Sarah, et al.
Publicado: (2022)

Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
por: Januel, Edouard, et al.
Publicado: (2023)

Siponimod: Disentangling disability and relapses in secondary progressive multiple sclerosis
por: Cree, Bruce AC, et al.
Publicado: (2020)

Risk Factors and Time to Clinical Symptoms of Multiple Sclerosis Among Patients With Radiologically Isolated Syndrome
por: Lebrun-Frénay, Christine, et al.
Publicado: (2021)

Comparative effectiveness of teriflunomide vs dimethyl fumarate in multiple sclerosis
por: Laplaud, David-Axel, et al.
Publicado: (2019)

Insights on the Relationship Between Hippocampal Connectivity and Memory Performances at the Early Stage of Multiple Sclerosis
por: Boscheron, Juliette, et al.
Publicado: (2021)

Comparison of Simoa(TM) and Ella(TM) to assess serum neurofilament‐light chain in multiple sclerosis
por: Gauthier, Audrey, et al.
Publicado: (2021)

Inflammatory-like presentation of CADASIL: a diagnostic challenge
por: Collongues, Nicolas, et al.
Publicado: (2012)

MD1003 (High-Dose Pharmaceutical-Grade Biotin) for the Treatment of Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis: A Randomized, Double-Blind, Placebo-Controlled Study
por: Tourbah, Ayman, et al.
Publicado: (2018)

Diagnosis and treatment of progressive multiple sclerosis: A position paper
por: Pozzilli, Carlo, et al.
Publicado: (2022)

Chronic lesion activity and disability progression in secondary progressive multiple sclerosis
por: Beynon, Vanessa, et al.
Publicado: (2022)

Prospects of siponimod in secondary progressive multiple sclerosis
por: McGinley, Marisa, et al.
Publicado: (2018)

Secondary Progressive Multiple Sclerosis: New Insights
por: Cree, Bruce A.C., et al.
Publicado: (2021)

Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
por: Vermersch, Patrick, et al.
Publicado: (2019)

Evaluation of no evidence of progression or active disease (NEPAD) in patients with primary progressive multiple sclerosis in the ORATORIO trial
por: Wolinsky, Jerry S., et al.
Publicado: (2018)

Natalizumab-PML survivors with subsequent MS treatment: Clinico-radiologic outcome
por: Maillart, Elisabeth, et al.
Publicado: (2017)

Comparative efficacy of fingolimod vs natalizumab: A French multicenter observational study
por: Barbin, Laetitia, et al.
Publicado: (2016)

The Epidemiology, Treatment Patterns and Economic Burden of Different Phenotypes of Multiple Sclerosis in Italy: Relapsing-Remitting Multiple Sclerosis and Secondary Progressive Multiple Sclerosis
por: Perrone, Valentina, et al.
Publicado: (2022)

Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2020)

Microstructural analyses of the posterior cerebellar lobules in relapsing-onset multiple sclerosis and their implication in cognitive impairment
por: Moroso, Amandine, et al.
Publicado: (2017)

Fampridine and quality of life in individuals with multiple sclerosis
por: Sagawa, Yoshimasa, et al.
Publicado: (2016)

Beta‐interferon exposure and onset of secondary progressive multiple sclerosis
por: Zhang, T., et al.
Publicado: (2015)

Urinary Excretion of Aluminium and Silicon in Secondary Progressive Multiple Sclerosis
por: Jones, Krista, et al.
Publicado: (2017)

Can We Treat Secondary Progressive Multiple Sclerosis Now?
por: Bhatia, Rohit, et al.
Publicado: (2019)

Correction to: Siponimod: A Review in Secondary Progressive Multiple Sclerosis
por: Scott, Lesley J.
Publicado: (2021)

Radiotherapy Improves the Disability in Patients with Secondary Progressive Multiple Sclerosis
por: Ebrahimi, Hossein-Ali, et al.
Publicado: (2023)

The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
por: Sharmin, Sifat, et al.
Publicado: (2023)

Disease duration of progression is helpful in identifying isolated bulbar palsy of amyotrophic lateral sclerosis
por: Zhang, Huagang, et al.
Publicado: (2021)

Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies
por: Coret, Francisco, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_tlb4c04jfi4k9lgaj5or940hkb